BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

552 related articles for article (PubMed ID: 2493506)

  • 21. Cellular and cytokine dependent monocyte-mediated leukemic cell death: modulation by interferon-gamma and tumor necrosis factor-alpha.
    van de Loosdrecht AA; Beelen RH; Ossenkoppele GJ; Broekhoven MG; Langenhuijsen MM
    Exp Hematol; 1993 Mar; 21(3):461-8. PubMed ID: 8440344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Natural cytotoxic cell-specific cytotoxic factor produced by IL-3-dependent basophilic/mast cells. Relationship to TNF.
    Richards AL; Okuno T; Takagaki Y; Djeu JY
    J Immunol; 1988 Nov; 141(9):3061-6. PubMed ID: 3262677
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Spontaneous cytotoxicity and tumor necrosis factor production by peripheral blood monocytes from AIDS patients.
    Wright SC; Jewett A; Mitsuyasu R; Bonavida B
    J Immunol; 1988 Jul; 141(1):99-104. PubMed ID: 3132506
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of cytostatic/cytotoxic lymphokines: relationship of natural killer cytotoxic factor to recombinant lymphotoxin, recombinant tumor necrosis factor, and leukoregulin.
    Ortaldo JR; Ransom JR; Sayers TJ; Herberman RB
    J Immunol; 1986 Nov; 137(9):2857-63. PubMed ID: 3093586
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Production of interferon and tumour necrosis factor by cloned human natural cytotoxic lymphocytes and T cells.
    Christmas SE; Meager A; Moore M
    Clin Exp Immunol; 1987 Aug; 69(2):441-50. PubMed ID: 2443292
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cytolytic activity of natural killer cells and lymphokine activated killer cells against hepatitis A virus infected fibroblasts.
    Baba M; Hasegawa H; Nakayabu M; Fukai K; Suzuki S
    J Clin Lab Immunol; 1993; 40(2):47-60. PubMed ID: 7932628
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anti-tumor cytotoxic potential and effect on human bone marrow GM-CFU of human LAK cells generated in response to various cytokines.
    Parhar RS; Ernst P; Sheth KV; al-Sedairy ST
    Eur Cytokine Netw; 1992; 3(3):299-306. PubMed ID: 1498260
    [TBL] [Abstract][Full Text] [Related]  

  • 28. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor necrosis factor and lymphotoxin secretion by human natural killer cells leads to antiviral cytotoxicity.
    Paya CV; Kenmotsu N; Schoon RA; Leibson PJ
    J Immunol; 1988 Sep; 141(6):1989-95. PubMed ID: 2844893
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Natural killer cell immunodeficiency in patients with chronic myelogenous leukemia. IV. Interleukin-1 deficiency, gamma-interferon deficiency and the restorative effects of short-term culture in the presence of interleukin-2 on natural killer cytotoxicity, natural killer-target binding and production of natural killer cytotoxic factor.
    Chang WC; Hsiao MH; Pattengale PK
    Nat Immun Cell Growth Regul; 1991; 10(2):57-70. PubMed ID: 1881400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tumor necrosis factor-alpha enhances cytolytic activity of human natural killer cells.
    Ostensen ME; Thiele DL; Lipsky PE
    J Immunol; 1987 Jun; 138(12):4185-91. PubMed ID: 3108384
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Analysis of the murine lymphokine-activated killer (LAK) cell phenomenon: dissection of effectors and progenitors into NK- and T-like cells.
    Kalland T; Belfrage H; Bhiladvala P; Hedlund G
    J Immunol; 1987 Jun; 138(11):3640-5. PubMed ID: 3495566
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated alpha 2-macroglobulin reverses the immunosuppressive activity in human breast cancer cell-conditioned medium by selectively neutralizing transforming growth factor-beta in the presence of interleukin-2.
    Harthun NL; Weaver AM; Brinckerhoff LH; Deacon DH; Gonias SL; Slingluff CL
    J Immunother; 1998 Mar; 21(2):85-94. PubMed ID: 9551359
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Mechanism of suppression of normal hemopoietic activity by lymphokine-activated killer cells and their products.
    Gibson FM; Malkovska V; Myint AA; Meager A; Gordon-Smith EC
    Exp Hematol; 1991 Aug; 19(7):659-63. PubMed ID: 1909968
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Toxic effects of interleukin-2-activated lymphocytes on vascular endothelial cells.
    Amador JF; Vazquez AM; Cabrera L; Barral AM; Gendelman R; Jondal M
    Nat Immun Cell Growth Regul; 1991; 10(4):207-15. PubMed ID: 1910152
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Accessory function of human fibroblasts in mitogen-stimulated interferon-gamma production by T lymphocytes. Inhibition by interleukin 1 and tumor necrosis factor.
    Le JM; Vilcek J
    J Immunol; 1987 Nov; 139(10):3330-7. PubMed ID: 3119705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Activation of human natural killer cells by lipopolysaccharide and generation of interleukin-1 alpha, beta, tumour necrosis factor and interleukin-6. Effect of IL-1 receptor antagonist.
    Conti P; Dempsey RA; Reale M; Barbacane RC; Panara MR; Bongrazio M; Mier JW
    Immunology; 1991 Aug; 73(4):450-6. PubMed ID: 1833315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. IL-4 inhibits IL-2 induction of LAK cytotoxicity in lymphocytes from a variety of lymphoid tissues.
    Colquhoun SD; Economou JS; Shau H; Golub SH
    J Surg Res; 1993 Nov; 55(5):486-92. PubMed ID: 8231167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interferon-gamma protects human endothelial cells from lymphokine-activated killer cell-mediated lysis.
    Renkonen R; Ristimäki A; Häyry P
    Eur J Immunol; 1988 Nov; 18(11):1839-42. PubMed ID: 3144455
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Analysis of the role of interferon-gamma, interleukin 2 and a third factor distinct from interferon-gamma and interleukin 2 in human B cell proliferation. Evidence that they act at different times after B cell activation.
    Romagnani S; Giudizi GM; Almerigogna F; Biagiotti R; Alessi A; Mingari C; Liang CM; Moretta L; Ricci M
    Eur J Immunol; 1986 Jun; 16(6):623-9. PubMed ID: 3087756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.